Penumbra (PEN) Stock Price
Penumbra Price
Revenue has compounded at 25.5% per year over the past 13 years to 1.40 B USD. Earnings per share have grown at 36.4% per year over the last 13 years. Penumbra's net margin stands at 12.7%, up from 0.4% several years earlier. Analysts set a median price target of 347.00 USD, implying 9.1% above the current price. Of 20 analysts, 6 rate the stock a buy — an overall Hold consensus.
Penumbra stock price
Penumbra business model & stock analysis
Frequently asked questions about Penumbra
Penumbra Inc operates under a business model that focuses on developing innovative medical devices and technologies. The company primarily specializes in designing, manufacturing, and marketing medical catheters and related products. Penumbra Inc aims to improve patient outcomes by providing medical professionals with advanced tools for the diagnosis and treatment of complex medical conditions, particularly in the fields of neurovascular and peripheral vascular diseases. With a commitment to research and development, Penumbra Inc aims to continually introduce cutting-edge medical solutions that address unmet clinical needs, ultimately improving the quality of life for patients around the world.
Penumbra Inc is primarily active in the healthcare industry.
The main competitors of Penumbra Inc in the market include Medtronic, Stryker Corporation, Johnson & Johnson, and Boston Scientific Corporation.
Penumbra Inc is a leading global healthcare company that specializes in innovative medical devices. Founded in 2004, Penumbra has consistently demonstrated its commitment to improving patient outcomes through ground-breaking technologies. Headquartered in Alameda, California, the company is renowned for its advanced products in neurovascular, neurosurgical, and peripheral vascular markets. With a strong emphasis on research and development, Penumbra has achieved significant milestones and gained recognition for its cutting-edge solutions. The company's dedication to improving patient care and its continuous pursuit of breakthrough technologies have solidified its position as a trusted leader in the medical device industry.
Penumbra Inc, a renowned medical device company, has achieved several significant milestones. One notable accomplishment was the development and success of their flagship product, the Penumbra System, for the treatment of ischemic stroke. This groundbreaking innovation has revolutionized stroke care by providing an effective solution to remove blood clots from cerebral vessels. Additionally, Penumbra Inc has achieved remarkable growth in expanding its product portfolio by introducing advanced neurovascular, peripheral vascular, and neurosurgical devices. The company's commitment to innovation, coupled with its strong clinical outcomes, has positioned Penumbra Inc as a leader in the field, benefiting patients worldwide.
Penumbra Inc is primarily present in multiple countries and regions across the globe. The company's presence extends to various regions, including North America, Europe, Asia-Pacific, Latin America, and the Middle East. With its headquarters in the United States, Penumbra Inc has established a strong presence in countries like Germany, France, China, Japan, Brazil, and the United Arab Emirates. By expanding their reach in different geographic regions, Penumbra Inc has successfully positioned themselves as a global player in the medical technology industry.
Penumbra Inc represents a set of core values and a corporate philosophy centered around innovation, patient care, and improving healthcare outcomes. With a focus on developing and delivering groundbreaking medical technologies, Penumbra is committed to pushing the boundaries of medical advancements to enhance patient treatment and improve quality of life. The company prioritizes collaboration with healthcare professionals, continuously seeks to understand unmet clinical needs, and aims to provide effective solutions through its cutting-edge products and therapies. Penumbra's dedication to excellence, integrity, and customer satisfaction drives its mission to transform the way healthcare is practiced globally.
Analysts currently set an average price target of 347.00 USD for the Penumbra stock (median: 347.00 USD), implying +9.1 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Penumbra stock: 6 recommend buying, 14 holding and 0 selling. For 2026, analysts expect Penumbra to generate revenue of 1.59 B USD and earnings per share of 4.69 USD.
Converted at the current exchange rate, the Penumbra share trades at 283.82 EUR (318.05 USD).
The Penumbra share (PEN) is listed on 5 stock exchanges, including: NYSE (PEN), SIX (Zürich) (0P8.SW), Frankfurt (0P8.F), München (0P8.MU), Düsseldorf (0P8.DU).
Penumbra Inc is a publicly traded company based in California, USA. The company operates in the medical technology and healthcare management sectors. Penumbra Inc was established in 2004 and has since continued to evolve. The company's product range and services encompass a wide spectrum and are used globally. The business model of Penumbra Inc consists of various divisions. The company's main activity lies in the manufacture of medical devices and instruments. Penumbra Inc specializes in the development of devices for neurointervention. These devices are used in the treatment of strokes or severe head injuries. The goal is to optimize patient care and increase chances of recovery. The product range of Penumbra Inc includes catheters, stents, coil systems, and software solutions for neurointervention, among others. These products are used worldwide and have established themselves in medical care. The devices and instruments of Penumbra Inc are known for their high quality and performance. Another division of Penumbra Inc is healthcare management. Under the umbrella brand "Penumbra System of Care," the company provides services for healthcare management. Analysis programs and training are offered to support hospitals and medical facilities in increasing their efficiency and optimizing patient care. Penumbra Inc also relies on innovative technologies and continually invests in research and development. The aim is to continuously improve medical care. The company works closely with experts and clinics to constantly optimize its products and services. In summary, the business model of Penumbra Inc is very diverse. Through its various divisions, the company can address a broad customer portfolio and flexibly respond to developments in the healthcare sector. The products and services of Penumbra Inc set standards in neurointervention and contribute to the improvement of medical care. Through continuous investment in research and development, Penumbra Inc is an innovation leader in the field of medical technology.
The expected revenue of Penumbra is 1.59 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Penumbra is 184.70 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Penumbra is currently 67.84. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Penumbra stock.
The price-to-sales ratio (P/S) of Penumbra is currently 7.88. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Penumbra stock.
The Eulerpool Quality Score for Penumbra is 6/10.
The ISIN of Penumbra is US70975L1070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Penumbra is A14Y65. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Penumbra is PEN. The ticker symbol is used to trade Penumbra shares on the stock exchange.
Penumbra stock
Penumbra Peer Group
Penumbra Ticker
Penumbra FIGI
All fundamentals and in-depth analysis of Penumbra
Our stock analysis for Penumbra stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Penumbra. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.